THE FUTURE IS HERE

Meet Cobalt™ ICDs and CRT-Ds

Medtronic

UNMATCHED FEATURE SUITE

- Extended longevity and higher output, while maintaining exclusive PhysioCurve™ size and shape
- Exclusive technology to reduce shocks
- Exclusive algorithms to optimize CRT
- Exclusive algorithms to manage atrial fibrillation (AF)

REIMAGINED CONNECTIVITY

BlueSync™ technology that enables tablet-based programming and app-based remote monitoring

STREAMLINED WORKFLOWS

Manage alerts of clinically relevant events with additional CareAlert™ notifications

THE FUTURE IS HERE

Meet Cobalt™ ICDs and CRT-Ds

UNMATCHED FEATURE SUITE

Extended Longevity

Mean longevity projections based on CareLink™ patient data*



*These values should not be interpreted as precise numbers. Individual patient results may vary based on their specific programming and experience.
†With AdaptivCRT™ programmed to BiV and LV.

Option for 40 J Energy Delivery on All Shocks (including first shock)[2,4,6]

MAXIMUM PROGRAMMED ENERGY	MAXIMUM DELIVERED ENERGY**	MAXIMUM STORED ENERGY††
40 J	40 J	47 J

** Energy delivered at connector block into a 50 Ω ± 1% load.

†† Energy stored at charge end on capacitor.

UNMATCHED FEATURE SUITE

PhysioCurve Design

PhysioCurve showed a 30% reduction in overall skin pressure compared to noncontoured devices.[7]

- Tapered at the head and bottom of device to reduce skin pressure and promote patient comfort
- Smaller footprint for a smaller incision
- Designed with lead wrap in mind — landing area to minimize additional stresses on the lead[8]

SmartShock™ 2.0 Technology

Lowest inappropriate shock rate.*[9]

SmartShock 2.0 includes six exclusive algorithms that discriminate true lethal arrhythmias from other arrhythmic and nonarrhythmic events.†[10]

1.5%
Inappropriate shock rate in dual and triple chamber patients at one year[9]

2.5%
Inappropriate shock rate in single chamber patients at one year[9]

*A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. Comparison of inappropriate shock rates based on survey of published literature.
†PR Logic™ does not apply to VR devices.

Exclusive Algorithms to Optimize CRT Delivery

AdaptivCRT™ Algorithm adapts to patients' changing needs by optimizing CRT pacing minute-to-minute

IMPROVEMENT IN CRT RESPONSE

12%
Improvement in CRT patient response with AdaptivCRT*[11]

RELATIVE REDUCTION IN MORTALITY

29%
AdaptivCRT is associated with a 29% relative reduction in mortality†[12]

REDUCTION IN HOSPITALIZATIONS

59%
Reduction in a patient's odds of 30-day HF readmission with AdaptivCRT[13]

*Comparing AdaptivCRT to Echo-optimized BiV pacing in patients with normal AV conduction, percentage of patients improved in Packer clinical composite score (CCS) at 6-month follow-up. CCS is a composite measure of mortality, HF hospitalizations, and symptomatic changes.
†Patients who received AdaptivCRT were associated with a 29% relative reduction in all-cause mortality vs. conventional CRT (after adjusting for other potential risk factors including age,gender, LVEF, NYHA class, QRS duration, AF, CAD, hypertension, AV block, and LBBB).

UNMATCHED FEATURE SUITE

Exclusive Algorithms to Manage AF

DETECT

Single Chamber

TruAF™ Detection Algorithm can detect AF in single chamber ICD patients using a traditional lead.

Dual Chamber and CRT-D

Highest published AF episode detection accuracy (PPV).*†[14-17]

AF Episode Detection Accuracy (PPV)*†[14]



*A controlled, head-to-head study evaluating the comparative performance of device algorithms has not been done. AF detection accuracy rates determined from independent clinical trials are presented for reference.
†Detection accuracy is compared using PPV, which is the percentage of all AT/AF episodes detected by the individual device detection algorithm that were adjudicated as true AT/AF.

Exclusive Algorithms to Manage AF

REDUCE

CRT-D

46% reduction in AF risk with AdaptivCRT Algorithm*[20]

*Most of the reduction in AF occurred in subgroups with prolonged AV conduction at baseline and with significant left atrial reverse remodeling.

Incidence of Primary End Point[20]
(≥ 48 consecutive hours of AT/AF)

Number	160	141	126	109	33
Remaining	312	280	260	241	83

Dual Chamber and CRT-D

36% relative reduction in AT/AF episodes ≥ 7 days with Reactive ATP™ Algorithm†[21]

†Compared to matched control group.

Incidence of AT/AF Events Lasting 7 or More Days[21]



Control	4,016	2,527	1,740	1,203	845
rATP	4,016	2,578	1,763	1,160	748

REIMAGINED CONNECTIVITY

BlueSync Technology

Crome ICDs and CRT-Ds with BlueSync technology enable secure, wireless communication.

Tablet-based CareLink SmartSync™ device manager

Cobalt ICDs and CRT-Ds

MyCareLink Heart™ mobile app or MyCareLink Relay™ Home Communicator

CareLink network

Supported by the Get Connected service

Increase Patient Adherence, Save Lives

Cardiac device patients who are not adherent with remote monitor transmissions will miss out on the following benefits:

50% potential increase in survival rate of patients[22-24]

35% potential reduction in ER visits[25,26]

18% potential reduction in length of hospital stay[27]



MyCareLink Heart results in **94.6% patient adherence to transmission schedule** compared to 77% patient adherence for bedside monitors.[28]

Security Measures[2,4,6]

BlueSync Technology

BlueSync technology security was designed to protect the device, patient data, and connectivity.

Device Protection

- **BlueSync devices do not accept programming from unauthorized sources.**
- **BlueSync devices are not connected to internet.** Devices do not have an IP address, unlike other connected consumer products.

Data Privacy

End-to-end encryption

Data are encrypted in BlueSync technology using NIST* government standard for security before it is transmitted to the CareLink network.

Please go to **medtronic.com/security** for up-to-date security information.

*NIST: National Institute of Standards and Technology.

Alternative Monitoring Option

MyCareLink Relay Home Communicator

A Bluetooth home communicator offers your patients an alternative option for easy and reliable monitoring.

- No manual pairing required
- Requires little to no user interaction

For patients who prefer not to use a smartphone.

MyCareLink Relay must be plugged in and patients must be within communication range for successful transmissions. Requires Wi-Fi or cellular connection.

STREAMLINED WORKFLOWS

Additional CareAlerts

Tachyarrhythmia Status:
- Monitored VT
- Weekly ATP delivered
- Daily VT/VF episodes

Bradyarrhythmia Status:
- Right ventricular pacing > 40%
- High capture thresholds

Heart Failure Status:
- Ventricular pacing < 90%
- OptiVol™ 2.0 Fluid Status Monitoring (CRT-D)

Meet Cobalt ICDs and CRT-Ds

Built for MRI

With Cobalt MRI, patients have access to 1.5T and 3T full body scanning*[2,4,6]

- Our SureScan™ devices and leads work in any combination.†
- Scanning conditions are simple: no MRI exclusion zone, no patient height restriction, no MRI duration restriction.[2,4,6]
- BiV pacing now available in MRI SureScan mode.[2]



*When MR conditions for use are met.
†For a complete list of approved device and lead combinations, please visit mrisurescan.com.

References

[1] Medtronic Claria MRI™ Quad CRT-D SureScan™ and Amplia MRI™ Quad CRT-D SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.

[2] Medtronic Cobalt™ HF Quad CRT-D MRI SureScan™ Model DTPB2QQ device manual.

[3] Medtronic Evera MRI™ XT DR SureScan™ and Evera MRI™ S DR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.

[4] Medtronic Cobalt™ DR MRI SureScan™ Model DDPB3D4 device manual.

[5] Medtronic Visia AF™ VR SureScan™ Mean Projected Service Life based on U.S. CareLink™ transmission data as of January 2019; UC201600236 EN.

[6] Medtronic Cobalt™ VR ICD MRI SureScan™ Model DVPB3D4 device manual.

[7] Flo D, et al. IS4/DF4 Device Shape Analysis. January 2013. Medtronic data on file.

[8] Lulic T. March 26, 2013. Medtronic data on file.

[9] Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. *Heart Rhythm*. May 2015;12(5):926-936.

[10] Volosin KJ, Exner DV, Wathen MS, Sherfesee L, Scinicariello AP, Gillberg JM. Combining shock reduction strategies to enhance ICD therapy: a role for computer modeling. *J Cardiovasc Electrophysiol*. March 2011;22(3):280-289.

[11] Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. *Heart Rhythm*. September 2013;10(9):1368-1374.

[12] Singh JP, Cha YM, Lunati M, et al. Real-world behavior of CRT pacing using the AdaptivCRT algorithm on patient outcomes: Effect on mortality and atrial fibrillation incidence. *J Cardiovasc Electrophysiol*. April 2020;31(4):825-833.

[13] Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. *JACC Heart Fail*. July 2015;3(7):565-572.

[14] Sprenger M. Comparison of Manufacturer's AT/AF Detection Accuracy across Clinical Studies. January 2015. Medtronic data on file.

[15] Pürerfellner H, Gillis AM, Holbrook, Hettrick DA. Accuracy of atrial tachyarrhythmia detection in implantable devices with arrhythmia therapies. *Pacing Clin Electrophysiol*. July 2004;27(7):983-992.

[16] Ziegler PD, et al. Accuracy of Atrial Fibrillation Detection in Implantable Pacemakers. Presented at HRS 2013 (PO02-08); Denver, CO.

[17] Medtronic data on file. QADoc DSN026170, Version 2.0, "AT/AF Duration Performance Comparison."

[18] Kauffman ES, Israel CW, Nair GM, et al. Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. *Heart Rhythm*. August 2012;9(8):1241-1246.

[19] Nowak B, McMeekin J, Knops M, et al. Validation of dual-chamber pacemaker diagnostic data using dual-channel stored electrograms. *Pacing Clin Electrophysiol*. July 2005;28(7):620-629.

[20] Birnie D, Hudnall H, Lemke B, et al. Continuous optimization of cardiac resynchronization therapy reduces atrial fibrillation in heart failure patients: Results of the Adaptive Cardiac Resynchronization Therapy Trial. *Heart Rhythm*. December 2017;14(12):1820-1825.

[21] Crossley GH, Padeletti L, Zweibel S, Hudnall JH, Zhang Y, Boriani G. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. *Pacing Clin Electrophysiol*. July 2019;42(7):970-979.

[22] Saxon LA, Hayes DL, Gilliam FR, et al. Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. *Circulation*. December 7, 2010;122(23):2359-2367.

[23] Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. Relationship between Level of Adherence to Automatic Wireless Remote Monitoring and Survival in Pacemaker and Defibrillator Patients. *J Am Coll Cardiol*. June 23, 2015;65(24): 2601-2610.

[24] Akar JG, Bao H, Jones PW, et al. Use of Remote Monitoring is Associated with Lower Risk of Adverse Outcomes Among Patients with Implanted Cardiac Defibrillators. *Circ Arrhythm Electrophysiol*. October 2015;8(5):1173-1180.

[25] Cronin EM, Ching EA, Varma N, Martin DO, Wilkoff BL, Lindsay BD. Remote monitoring of cardiovascular devices: a time and activity analysis. *Heart Rhythm*. December 2012;9(12): 1947-1951.

[26] Varma N. Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study. *Am Heart J*. December 2007;154(6):1029-1034.

[27] Crossley GH, Boyle A, Vitense H, Chang Y, Mead RH; CONNECT Investigators. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. *J Am Coll Cardiol*. March 8, 2011;57(10):1181-1189.

[28] Tarakji KG, Zaidi AM, Zweibel SL, et al. Performance of First in the World Pacemaker to Use Smart Device App for Remote Monitoring. Available at: https://www.heartrhythm365.org/Public/Catalog/Home.aspx. Accessed April 30, 2020.

This material does not replace or supersede the instructions for use. It should not be considered the exclusive source of information, and should be used in conjunction with the device manual.

See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan™ device, see the MRI SureScan™ technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu

For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
www.medtronic.eu
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

United Kingdom/Ireland
Medtronic Limited
Building 9
Croxley Park
Hatters Lane
Watford
Herts WD18 8WW
www.medtronic.co.uk
Tel: +44 (0)1923 212213
Fax: +44 (0)1923 241004

medtronic.eu